These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8078843)

  • 1. [Low molecular weight heparins. No increase of the cost of treatment of deep venous thrombosis].
    Levesque H; Cailleux N; Courtois H
    Presse Med; 1994 Apr 30-May 7; 23(17):816. PubMed ID: 8078843
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost effectiveness and ease of administration of low molecular weight heparin in deep vein thrombosis.
    Teo CP; Lim HL; Kueh YK
    Thromb Haemost; 1994 Aug; 72(2):328-9. PubMed ID: 7831676
    [No Abstract]   [Full Text] [Related]  

  • 3. [Evaluation of hospital cost of six days of treatment of deep venous thrombosis. Comparison of subcutaneous nadroparin and intravenous heparin in 40 patients].
    Lévesque H; Cailleux N; Vasse D; Legallicier B; Moore N; Borg JY; Hantute N; Thuillez C; Courtois H
    Therapie; 1994; 49(2):101-5. PubMed ID: 7817331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation of the use of nadroparin in the treatment of deep-vein thrombosis in Switzerland.
    Lloyd AC; Aitken JA; Hoffmeyer UK; Kelso EJ; Wakerly EC; Barber ND
    Ann Pharmacother; 1997; 31(7-8):842-6. PubMed ID: 9220041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should low-molecular-weight heparins replace unfractionated heparin as the agent of choice for adults with deep venous thrombosis?
    Brewer D
    J Fam Pract; 1998 Sep; 47(3):185-92. PubMed ID: 9752370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of the use of nadroparin calcium in the prophylaxis of deep vein thrombosis and pulmonary embolism in surgical patients in Italy.
    Lloyd A; Aitken JA; Hoffmeyer UK; Kelso EJ; Wakerly EC; Barber ND
    Pharmacoeconomics; 1997 Oct; 12(4):475-85. PubMed ID: 10174313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapy of thromboses with low-molecular-weight heparins].
    Haas S; Haas P
    Wien Med Wochenschr; 1999; 149(2-4):39-45; discussion 45. PubMed ID: 10378321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-molecular-weight heparins for the treatment of deep-vein thrombosis.
    Cziraky MJ; Spinler SA
    Clin Pharm; 1993 Dec; 12(12):892-9. PubMed ID: 8137606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of ambulatory and inpatient treatment of acute deep venous thrombosis of the leg: subjective and economic aspects].
    Frank D; Blättler W
    Schweiz Med Wochenschr; 1998 Sep; 128(36):1328-33. PubMed ID: 9784675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary prophylaxis with low molecular weight heparin: the dose?
    Horne MK
    Thromb Haemost; 2001 Oct; 86(4):1129. PubMed ID: 11686343
    [No Abstract]   [Full Text] [Related]  

  • 11. Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery.
    Nurmohamed MT; van Riel AM; Henkens CM; Koopman MM; Que GT; d'Azemar P; Büller HR; ten Cate JW; Hoek JA; van der Meer J; van der Heul C; Turpie AG; Haley S; Sicurella A; Gent M
    Thromb Haemost; 1996 Feb; 75(2):233-8. PubMed ID: 8815566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis--an economic evaluation. TASMAN Study Group.
    van den Belt AG; Bossuyt PM; Prins MH; Gallus AS; Büller HR
    Thromb Haemost; 1998 Feb; 79(2):259-63. PubMed ID: 9493572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of low molecular weight heparins (LMWH) in the prevention of venous thromboembolism (VTE).
    Kakkar VV
    Thromb Haemost; 1995 Jul; 74(1):364-8. PubMed ID: 8578486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of deep venous thrombosis with low molecular weight heparins.
    Ruiz F; Berman D
    West J Med; 1998 Mar; 168(3):186-7. PubMed ID: 9549422
    [No Abstract]   [Full Text] [Related]  

  • 15. Hemostatic activation under anticoagulant treatment: a comparison of unfractionated heparin vs. nadroparin in the treatment of proximal deep vein thrombosis.
    Stricker H; Marchetti O; Haeberli A; Mombelli G
    Thromb Haemost; 1999 Oct; 82(4):1227-31. PubMed ID: 10544903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of venous thrombosis with low molecular weight heparin. Progress and outlook].
    Fiessinger JN
    Bull Acad Natl Med; 1997 May; 181(5):875-83; discussion 883-5. PubMed ID: 9312362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Health care economics evaluation of inpatient treatment of venous thrombosis with unfractionated heparin versus subcutaneous low molecular weight heparin at home].
    Osterkorn D; Schramm W; Szucs T
    Med Klin (Munich); 1996 Sep; 91(9):607-9. PubMed ID: 8984321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis.
    Lensing AW; Prins MH; Davidson BL; Hirsh J
    Arch Intern Med; 1995 Mar; 155(6):601-7. PubMed ID: 7887755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Standard heparin versus low-molecular-weight heparin].
    Lockner D
    Wien Med Wochenschr; 1999; 149(2-4):37-8. PubMed ID: 10378320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France.
    Fraisse F; Holzapfel L; Couland JM; Simonneau G; Bedock B; Feissel M; Herbecq P; Pordes R; Poussel JF; Roux L
    Am J Respir Crit Care Med; 2000 Apr; 161(4 Pt 1):1109-14. PubMed ID: 10764298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.